SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies.

Authors

Hailong Guo
Sha Ha
Jason W Botten
Kai Xu
Ningyan Zhang
Zhiqiang An
William R Strohl
John W Shiver
Tong-Ming Fu

Publication Date

4-28-2024

Journal

Viruses

Abstract

Since the SARS-CoV-2 Omicron virus has gained dominance worldwide, its continual evolution with unpredictable mutations and patterns has revoked all authorized immunotherapeutics. Rapid viral evolution has also necessitated several rounds of vaccine updates in order to provide adequate immune protection. It remains imperative to understand how Omicron evolves into different subvariants and causes immune escape as this could help reevaluate the current intervention strategies mostly implemented in the clinics as emergency measures to counter the pandemic and, importantly, develop new solutions. Here, we provide a review focusing on the major events of Omicron viral evolution, including the features of spike mutation that lead to immune evasion against monoclonal antibody (mAb) therapy and vaccination, and suggest alternative durable options such as the ACE2-based experimental therapies superior to mAbs to address this unprecedented evolution of Omicron virus. In addition, this type of unique ACE2-based virus-trapping molecules can counter all zoonotic SARS coronaviruses, either from unknown animal hosts or from established wild-life reservoirs of SARS-CoV-2, and even seasonal alpha coronavirus NL63 that depends on human ACE2 for infection.

Keywords

SARS-CoV-2, Humans, Immune Evasion, COVID-19, Spike Glycoprotein, Coronavirus, Angiotensin-Converting Enzyme 2, Animals, Evolution, Molecular, Antibodies, Monoclonal, Mutation, COVID-19 Vaccines, Antibodies, Viral, SARS-CoV-2, evolution, ACE2, therapy

Comments

PMID: 38793580